Pragmatism Leads the Way: Industry-Finance Synergy Builds the Foundation for High-Quality Development in the Healthcare Sector

In recent years, the global pharmaceutical and healthcare industry has witnessed rapid development. On one hand, breakthroughs in biotechnology have opened up limitless possibilities for new drug development. Emerging frontier technologies such as gene editing, cell therapy, and precision medicine are providing new avenues for treating refractory diseases. On the other hand, driven by heightened health awareness and increased purchasing power, demand in the pharmaceutical and healthcare market continues to grow, particularly in areas such as oncology, neurodegenerative diseases, and metabolic disorders, where market potential is substantial. Innovation has become the key to high-quality development for enterprises and the entire pharmaceutical and healthcare industry, while sci-tech finance serves as the optimal driver supporting corporate growth.

However, behind this prosperous landscape lie numerous uncertainties and risks. High R&D costs, lengthy development cycles, complex approval processes, and intense market competition have placed immense pressure on pharmaceutical and healthcare companies. Furthermore, changes in the policy environment, the persistent uncertainty of regional international conflicts, upstream supply chain shortages, and anti-corruption campaigns in the healthcare sector have cast a shadow over the industry’s development. These challenges have led some industry insiders to hold a pessimistic view of the future of the pharmaceutical and healthcare industry.“Doomsaying”The sound occasionally rings out.

In the face of various challenges and pessimistic narratives, reshaping positive outlooks on its future both within and outside the industry hinges on moving beyond the efforts of individual entities to building and strengthening an ecosystem-wide collaborative framework. Amid this urgent need for transformation, regional industrial clusters have naturally emerged as a critical pathway leading the industry toward positive development, representing a force that cannot be overlooked.

Regional industrial clusters are not merely a phenomenon of geographic agglomeration, but a concentrated embodiment of innovation and collaborative spirit. Acting as a catalyst, they foster close cooperation and healthy competition among enterprises, accelerating the cyclical flow of knowledge capital and technological innovation. This clustering effect not only enhances the individual competitiveness of enterprises within the region but also shapes the unique advantages of the regional brand as a whole, strengthening adaptability to external changes and resilience against risks.

Beijing, leveraging its unique geographic location, abundant scientific research resources, and robust policy support, has emerged as the leading city in China’s pharmaceutical and healthcare industry. Changping District, as a key hub for this sector in Beijing, regards it as a new engine for regional economic development. Here, high-end medical institutions, top-tier R&D centers, and innovative enterprises are closely integrated, jointly weaving an industrial ecosystem that covers the entire chain of R&D, production, and services. The establishment of this ecosystem has not only enhanced the overall competitiveness of the pharmaceutical and healthcare industry in Changping District and Beijing but also laid a solid foundation for the sustainable development of the sector.

Of particular note, Changping District has provided a steady stream of “financial vitality” to the development of the pharmaceutical and health industry through the Changping Science and Technology Industry Fund of Funds cluster, with Chang Development Group serving as the primary platform. These funds have accelerated the translation of scientific and technological achievements into industrial applications, injecting strong momentum into the growth of the pharmaceutical and health sector in Beijing and across China.

Limited seats available. Please scan the QR code to register.

At this juncture, in the face of challenges and pessimistic narratives surrounding the pharmaceutical and healthcare industry, Changping District has chosen to promote high-quality development through pragmatic attitudes and actions. To further deepen this process, Changping District successfully launched the ever-lasting International Forum on Life Sciences in November 2022. During the same period, the most notable highlight was2022 Pharmaceutical and Healthcare Finance & Investment Innovation Forum, focusing on multiple sectors including biopharmaceuticals, medical devices, and smart healthcare, the forum extended prestigious invitations to leading investment institutions, luminaries in the life sciences, and representatives of outstanding innovative startups to convene online. Even in 2022, a year marked by intertwined challenges both within and outside the industry, the forum still attracted nearly one million online viewers, demonstrating its substantial influence and appeal.

Academician Shao Feng, Deputy Director of Scientific Research at the National Institute of Biological Sciences, Beijing:“Basic scientific research is the lighthouse of the pharmaceutical and healthcare sector, while financial empowerment serves as the key driving force propelling it to illuminate the future.”

Li Xiang, Managing Director and Member of the Investment Banking Business Management Committee at CICC:“Amid a volatile global economy and normalized pandemic prevention and control, the healthcare industry is ushering in new opportunities in the capital market, with the A-share market continuing to serve as fertile ground for the growth of pharmaceutical companies.”

He Wenbin, Co-Chief Healthcare Analyst at Haitong Securities:“In the post-pandemic era, the pharmaceutical sector is ushering in a new wave of development driven by hard technology. The flourishing of innovative medical devices, coupled with the moderate impact of centralized procurement, has jointly injected new momentum into the industry’s steady growth.”

Yuan Quanhong, Partner at Hankang Capital:“Driven by the dual forces of policy support and market demand, the biopharmaceutical industry is entering a new phase of rapid development, and China’s innovation in drug R&D and industrialization will be accelerated.”

Cai Daqing, Founding Partner of Sherpa Capital:“China’s medical device innovation has gradually entered the Innovation 4.0 (disruptive) stage, transcending the boundaries of innovation and making a remarkable transformation from ‘Made in China’ to ‘Intelligently Made in China,’ thereby leading the new global trend in health technology.”

Yang Ruirong, Partner at Yuanyi Capital:“China’s digital healthcare sector boasts broad prospects and may be on the verge of a ‘catch-up’ opportunity. By integrating medical, technological, and insurance resources, it is poised to achieve a dual enhancement in service efficiency and market value.”

“Focusing on Biopharmaceuticals, Anchoring in the Golden Track” Panelists:“Amid a volatile global economy, China’s biopharmaceutical industry still holds investment potential; only by strengthening core competitiveness can it advance steadily.”

“Thorny Path, Long Journey: The Thorns and Fruits of Medical Device Investment” Guest Speakers:“Investment risks and opportunities coexist; innovation continues to lead the medical device industry to new heights. Amidst the ever-changing economic landscape, the sector will continue to advance steadily.”

“Digital Empowerment Ushers in a New Era of Healthcare” Panelists:“The digitalization of healthcare is an irreversible trend; investors and entrepreneurs alike should maintain confidence and patience, as the industry will ultimately usher in a new era of comprehensive health.”

Looking back at the profound insights shared by the guests, it is evident that the positive energy embedded in their views not only provided a precise analysis of the challenges facing the industry but also revealed new opportunities and pathways for the healthcare industry under the new landscape from multiple dimensions. These forward-thinking perspectives laid a solid foundation for the successful hosting of the 2nd Changping Medical Health Financial Investment Innovation Forum in 2023. Building on the enthusiastic response and far-reaching impact of the first forum,The 2nd Changping Medical and Health Finance Investment Innovation Forum convened as scheduled in 2023, bringing together a broader spectrum of industry elites and financial leaders with heightened expectations and deeper inquiry to discuss how sci-tech finance can empower new frontiers in healthcare. This forum served not only as a testament to Changping District’s commitment to fostering high-quality development in the pharmaceutical and health industries but also as a significant milestone for the sector in seeking breakthroughs and pursuing collaborative growth amidst adversity.

Limited seats available; please scan the QR code to register.

As the hands of time gently turn to a new chapter in 2024, Changping District is poised to unleash an unprecedented storm—2024 Changping Medical and Health Finance Investment Innovation Forum, this forum will be held onNovember 22, 2024held in Beijing, with“Synergizing Industry and Finance, Quality Innovates the Future”with the theme of, byPeople's Government of Changping District, Beijing Municipality; Beijing State-owned Capital Operation and Management Co., Ltd.Hosted by,Future Science City Management Committee (Life Science Park Management Committee), Zhongguancun Science Park Changping Park Management Committee, Beijing Changping District Development and Reform Commission, Beijing Changping Science and Technology Park Development Group Co., Ltd., Beijing Changke Jin Investment Co., Ltd., Chongqing Dongmaicheng Technology Co., Ltd. (VCBeat VB100)Co-hosted to bring together government leaders, industry experts, corporate executives, and financial investment elites, jointly creating a brilliant feast that inspires future wisdom, stimulating the intense collision of innovative thinking and financial capital, and leading the industry towards a higher quality development stage.Here are the Top 10 Highlight Topics of This Forum:

It is clear that in this upcoming grand event, innovative thinking and financial capital will collide intensely, sparking brilliant flashes of inspiration. Changping District has been actively mobilizing various stakeholders, and we have every reason to believe that, amid the surging wave of innovation in pharmaceuticals and healthcare, the convergence of government, industry, academia, research, medical institutions, and investment sectors will accelerate communication and collaboration among all ecosystem participants, thereby providing sustained and powerful momentum for the high-quality development of the pharmaceutical, healthcare, and financial investment industries in the future.

This is an era driven by innovation, empowered by data, and characterized by cross-sector integration. Standing at the crossroads of unprecedented growth in the pharmaceutical and healthcare industry, the future of this sector is brimming with extraordinary opportunities and infinite possibilities. With full confidence, anticipation, and a commitment to our original aspiration of “pragmatism,” weNovember 22, 2024InBeijing Jiuhua Villa Convention HotelSound the assembly call for the 2024 Medical and Healthcare Financial Investment Innovation Forum; let us join hands to forge a brilliant new chapter for China’s medical and healthcare industry!